Inositol: history of an effective therapy for Polycystic Ovary Syndrome

被引:2
|
作者
Bizzarri, M. [1 ]
Carlomagno, G. [2 ]
机构
[1] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy
[2] LoLiPharma Srl, Dept Med, Rome, Italy
关键词
Inositol; Polycistic ovary syndrome; PCOS; D-CHIRO-INOSITOL; SPERM INJECTION CYCLES; IMPROVE OOCYTE QUALITY; IN-VITRO FERTILIZATION; DOUBLE-BLIND TRIAL; INSULIN-RESISTANCE; MYOINOSITOL SUPPLEMENTATION; OVULATION INDUCTION; OVERWEIGHT PATIENTS; NONOBESE PATIENTS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inositol is a physiological compound belonging to the sugar family. The two inositol stereoisomers, myo-inositol and D-chiroinositol are the two main stereisomers present in our body. Myo-inositol is the precursor of inositol triphosphate, a second messenger regulating many hormones such as TSH, FSH and insulin. D-chiroinositol is synthetized by an insulin dependent epimerase that converts myo-inositol into D-chiro-inositol. Polycistic Ovary Syndrome (PCOS) is a metabolic and hormonal disorder and a common cause of infertility. Insulin resistance and the consequent hyperinsulinaemia contribute to hyperandrogenism development, typical marker of PCOS. In these patients myo and/or D-chiro-inositol administration improves insulin sensivity while only myo-inositol is a quality marker for oocytes evaluation. Myo-inositol produces second messengers for FSH and glucose uptake, while D-chiroinositol provides second messengers promoting glucose uptake and glycogen synthesis. The physiological ratio of these two isomers is 40:1 (MI/DCI) and seems to be an optimal approach for the treatment of PCOS disorders.
引用
收藏
页码:1896 / 1903
页数:8
相关论文
共 50 条
  • [31] The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review
    Gateva, Antoaneta
    Unfer, Vittorio
    Kamenov, Zdravko
    GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (07) : 545 - 550
  • [32] Increased Circulating Levels of Myo-inositol in Girls with Polycystic Ovary Syndrome
    Bahadir, Nisan Ucer
    Guler, Eray Metin
    Kale, Ebru
    Aktas, Selman
    Cakir, Aydilek Dagdeviren
    Sutcu, Zumrut Kocabey
    Esen, Firuzan
    Beyaztas, Hakan
    Dastan, Ali Imran
    Ucar, Ahmet
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 2): : 375 - 376
  • [33] The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole
    Sajadeh Pourghasem
    Fatemeh Bazarganipour
    Seyed Abdolvahab Taghavi
    Maryam Azizi Kutenaee
    Archives of Gynecology and Obstetrics, 2019, 299 : 1193 - 1199
  • [34] The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole
    Pourghasem, Sajadeh
    Bazarganipour, Fatemeh
    Taghavi, Seyed Abdolvahab
    Kutenaee, Maryam Azizi
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 299 (04) : 1193 - 1199
  • [35] Criteria for the choice of supplementation with inositol and lipoic acid in patients with polycystic ovary syndrome
    Genazzani, Alessandro D.
    MINERVA GINECOLOGICA, 2020, 72 (05): : 277 - 280
  • [36] The Role of Myo-Inositol in the regulation of female hormones and Polycystic Ovary Syndrome
    Martinez-Loria, Hazel Johanna
    Vargas-Zuniga, Lester Fabian
    Gonzalez-Vargas, Joshua Andrey
    Cordero-Robles, Kristel Mariana
    Urrea-Mayorga, Maria Jose
    TECNOLOGIA EN MARCHA, 2024, 37 (04): : 133 - 140
  • [37] Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes
    DiNicolantonio, James J.
    O'Keefe, James
    OPEN HEART, 2022, 9 (01):
  • [38] Exercise therapy in polycystic ovary syndrome: a systematic review
    Harrison, Cheryce L.
    Lombard, Catherine B.
    Moran, Lisa J.
    Teede, Helena J.
    HUMAN REPRODUCTION UPDATE, 2011, 17 (02) : 171 - 183
  • [39] A NEW APPROACH TO THE COMBINATION THERAPY OF POLYCYSTIC OVARY SYNDROME
    Semenyna, H. B.
    Shatylovych, K. L.
    Fartushok, T., V
    Komissarova, O. S.
    Yurchyshyn, O. M.
    WORLD OF MEDICINE AND BIOLOGY, 2020, 72 (02): : 125 - 129
  • [40] Perspectives on Polycystic Ovary Syndrome: Is Polycystic Ovary Syndrome Research Underfunded?
    Brakta, Soumia
    Lizneva, Daria
    Mykhalchenko, Kateryna
    Imam, Adonis
    Walker, Walidah
    Diamond, Michael P.
    Azziz, Ricardo
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (12): : 4421 - 4427